FOLD Stock Overview
A biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for FOLD from our risk checks.
Amicus Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.87 |
| 52 Week High | US$14.57 |
| 52 Week Low | US$9.02 |
| Beta | 0.67 |
| 11 Month Change | -15.57% |
| 3 Month Change | -11.95% |
| 1 Year Change | -6.71% |
| 33 Year Change | -7.84% |
| 5 Year Change | -8.10% |
| Change since IPO | -31.60% |
Recent News & Updates
Here's Why Amicus Therapeutics (NASDAQ:FOLD) Has A Meaningful Debt Burden
Nov 10
Amicus: Teva Settlement Clears Revenue Path Forward For Galafold
Oct 18'Boring' Amicus Therapeutics Is Making Progress
Sep 29Amicus Therapeutics: A Compelling Investment In The Rare Disease Biotech Sector
Aug 16Recent updates
Here's Why Amicus Therapeutics (NASDAQ:FOLD) Has A Meaningful Debt Burden
Nov 10Amicus: Teva Settlement Clears Revenue Path Forward For Galafold
Oct 18'Boring' Amicus Therapeutics Is Making Progress
Sep 29Amicus Therapeutics: A Compelling Investment In The Rare Disease Biotech Sector
Aug 16Little Excitement Around Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues
Jul 02Here's Why Amicus Therapeutics (NASDAQ:FOLD) Can Afford Some Debt
Jun 06Amicus Therapeutics: Too Cheap At Under $10 A Share
May 20Amicus Therapeutics, Inc. (NASDAQ:FOLD) Looks Inexpensive But Perhaps Not Attractive Enough
Mar 27Amicus Therapeutics: Expect Improved Commercial Momentum In 2024
Feb 29Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Share Price Could Signal Some Risk
Dec 19Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt
Jul 06Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues Are Not Doing Enough For Some Investors
May 14Does Amicus Therapeutics (NASDAQ:FOLD) Have A Healthy Balance Sheet?
Mar 23We Think Amicus Therapeutics (NASDAQ:FOLD) Has A Fair Chunk Of Debt
Dec 06Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt
Aug 25Amicus Therapeutics: AT-GAA Approval Delayed, I Will Continue Holding
Aug 10Amicus Therapeutics Q2 2022 Earnings Preview
Aug 03Shareholder Returns
| FOLD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.7% | 4.0% | 2.0% |
| 1Y | -6.7% | 18.0% | 32.4% |
Return vs Industry: FOLD underperformed the US Biotechs industry which returned 18.3% over the past year.
Return vs Market: FOLD underperformed the US Market which returned 32.6% over the past year.
Price Volatility
| FOLD volatility | |
|---|---|
| FOLD Average Weekly Movement | 5.7% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: FOLD has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: FOLD's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 517 | Brad Campbell | amicusrx.com |
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline.
Amicus Therapeutics, Inc. Fundamentals Summary
| FOLD fundamental statistics | |
|---|---|
| Market cap | US$2.90b |
| Earnings (TTM) | -US$104.69m |
| Revenue (TTM) | US$493.67m |
6.0x
P/S Ratio-28.2x
P/E RatioIs FOLD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FOLD income statement (TTM) | |
|---|---|
| Revenue | US$493.67m |
| Cost of Revenue | US$49.43m |
| Gross Profit | US$444.24m |
| Other Expenses | US$548.93m |
| Earnings | -US$104.69m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.35 |
| Gross Margin | 89.99% |
| Net Profit Margin | -21.21% |
| Debt/Equity Ratio | 217.8% |
How did FOLD perform over the long term?
See historical performance and comparison